Houston-based TRISH's research will be done aboard the Polaris Dawn by its crew, which includes, from left to right, Mission Specialist and Medical Officer Anna Menon, Mission Pilot Scott “Kidd” Poteet, Mission Commander Jared “Rook” Isaacman, Mission Specialist Sarah Gillis. Photo courtesy Polaris Program/John Kraus

The Translational Research Institute for Space Health at Baylor College of Medicine, or TRISH, announced this month that it will perform research experiments aboard SpaceX's upcoming Polaris Dawn mission that will look into everything from human vision to motion sickness to radiation levels while in space.

The research aboard Polaris Dawn will complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit, which was also operated by SpaceX in 2021.

“The Institute’s mission is to help humans thrive in deep space,” Dr. Dorit Donoviel, TRISH executive director and associate professor for the Center for Space Medicine at Baylor, said in a statement. “We are grateful to our commercial space exploration partners, and in particular, the Polaris Program, who recognize how important it is to carry out and support health research in their missions, as a route to improving health for all humans in space and on Earth.”

Polaris Dawn is slated to launch from NASA’s Kennedy Space Center in Florida no earlier than March 2023. It is part of SpaceX's Polaris Program, which proposes three space missions. The first mission aims to reach the highest Earth orbit ever flown.

Four crew members will be onboard SpaceX’s Falcon 9 rocket for the Polaris Dawn mission. TRISH's experiments are part of 38 experiments from institutions that will be conducted on board at high-altitude Earth orbit.

The experiments are supported by federal funding from TRISH's cooperative agreement with NASA, as well as a donation from the Polaris Program.

According to a statement from TRISH, the experiments will include the following:

  • Collecting data related to the vision condition Spaceflight Associated Neuro-Ocular Syndrome (SANS), which is a top risk to human health in long-duration spaceflight
  • Quantifying alterations in body composition and fluid distribution during exposure to weightlessness
  • Directly measuring intracranial pressure changes to quantify the effects of weightlessness on the brain
  • Measuring cognitive performance, which reflects fitness for duty
  • Collecting biometric data to track physiologic changes, which could inform on changes in overall health
  • Using miniaturized, intelligent ultrasound to train the astronauts to scan themselves and deliver medical quality images
  • Testing ways to predict space motion sickness to improve crew safety and in-mission performance
  • Collecting data on the radiation environment to observe how space radiation may affect human systems
  • Providing biological samples for multi-omics analyses and storage in a long-term biobank to be available to researchers in the future

TRISH launched the first-ever commercial spaceflight medical research program in 2021, known as the Expand—Enhancing Exploration Platforms and Analog Definition—Program. Future findings from the Polaris Dawn mission will be added to the database, which compiles in-flight health data from multiple spaceflights.

TRISH was founded in 2016 with the mission of addressing the most pressing health risks and challenges associated with human deep space exploration.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.